Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival
- PMID: 17640713
- DOI: 10.1016/j.humpath.2007.03.014
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival
Abstract
Chemotherapy resistance is a significant contributor to treatment failure and death in men with hormone-refractory prostate cancer. One unexplored mechanism for drug resistance is the induction of stress response proteins referred to as the glucose-regulated proteins (GRPs). We sought to determine the level of expression of GRP78, the best characterized GRP in lymph node-positive prostate cancer. Archived, paraffin-embedded, radical prostatectomy specimens were obtained from 153 patients with lymph node-positive prostate cancer (stage D1). The level of GRP78 expression was determined by immunohistochemistry. We assessed the expression and specificity of GRP78 immunoreactivity in benign prostatic tissue, prostate cancer, and lymph node metastasis. We correlated the intensity of immunopositivity with prostate cancer recurrence and survival. Whereas immunohistochemical staining demonstrated that all prostate tissue was immunoreactive for GRP78, the intensity of expression was markedly higher in the primary tumor compared with areas of benign epithelium. GRP78 expression was also evident in lymph node metastases although less intensely than in the primary tumor. Patients with strong GRP78 immunoreactivity in the primary tumor are at higher risk for clinical recurrence (relative risk = 2.0, P = .019) and death (relative risk = 1.8, P = .024) than patients with weak GRP78 expression. This finding confirms that GRP78 protein expression is significantly higher in prostate cancer than in benign prostatic tissue. The intensity of expression is significantly associated with survival and clinical recurrence. GRP78 has considerable potential not only as a prognostic indicator but also as a potential therapeutic target.
Similar articles
-
GRP78 induction in cancer: therapeutic and prognostic implications.Cancer Res. 2007 Apr 15;67(8):3496-9. doi: 10.1158/0008-5472.CAN-07-0325. Cancer Res. 2007. PMID: 17440054 Review.
-
Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.Urol Oncol. 2007 Mar-Apr;25(2):134-40. doi: 10.1016/j.urolonc.2006.07.019. Urol Oncol. 2007. PMID: 17349528
-
Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5987-93. doi: 10.1158/1078-0432.CCR-06-0133. Clin Cancer Res. 2006. PMID: 17062670
-
Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome.Cancer. 2006 Aug 1;107(3):439-50. doi: 10.1002/cncr.22034. Cancer. 2006. PMID: 16795064 Review.
-
Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.Urology. 2006 Jun;67(6):1247-52. doi: 10.1016/j.urology.2005.12.009. Epub 2006 May 12. Urology. 2006. PMID: 16697447
Cited by
-
Impact of Obesity-Related Endoplasmic Reticulum Stress on Cancer and Associated Molecular Targets.Biomedicines. 2024 Apr 3;12(4):793. doi: 10.3390/biomedicines12040793. Biomedicines. 2024. PMID: 38672148 Free PMC article. Review.
-
Introduction of a new recombinant vaccine based on GRP78 for breast cancer immunotherapy and evaluation in a mouse model.Bioimpacts. 2024;14(2):27829. doi: 10.34172/bi.2023.27829. Epub 2023 Sep 18. Bioimpacts. 2024. PMID: 38505675 Free PMC article.
-
Endoplasmic Reticulum Stress and Cancer: Could Unfolded Protein Response Be a Druggable Target for Cancer Therapy?Int J Mol Sci. 2023 Jan 13;24(2):1566. doi: 10.3390/ijms24021566. Int J Mol Sci. 2023. PMID: 36675080 Free PMC article. Review.
-
Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy.Front Immunol. 2022 Dec 5;13:1066185. doi: 10.3389/fimmu.2022.1066185. eCollection 2022. Front Immunol. 2022. PMID: 36544781 Free PMC article.
-
The endoplasmic reticulum stress response in prostate cancer.Nat Rev Urol. 2022 Dec;19(12):708-726. doi: 10.1038/s41585-022-00649-3. Epub 2022 Sep 27. Nat Rev Urol. 2022. PMID: 36168057 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous